In a move set to strengthen India’s position as a global hub for medical device manufacturing, the Ministry of Health and Family Welfare has proposed key amendments to the Medical Devices Rules, 2017. The draft notification signals a strong push toward transparency, standardization, and investor-friendly regulation—creating fresh opportunities for Indian manufacturers and investors.
The draft has been released for public consultation, with stakeholders invited to submit feedback within 30 days.
A Boost for Indian Manufacturers and Investors
The proposed amendments reflect the government’s commitment to building a robust, predictable, and transparent regulatory ecosystem—a critical factor for attracting domestic investment and scaling local manufacturing.
Looking For a Medical Device Regulatory Consultant?
Let’s have a word about your next project
Key Business-Friendly Highlights
- Clear Regulatory Framework
The introduction of a formal definition for “Certificate of Registration” brings clarity and uniformity, making compliance easier for manufacturers and reducing regulatory ambiguity. - Strengthened Supply Chain Transparency
Mandatory labeling of outsourced sterilization facilities ensures traceability and quality assurance—enhancing trust in Indian-made medical devices both domestically and globally. - Standardized Testing Costs (Major Investor Advantage)
The introduction of a structured Ninth Schedule for testing fees eliminates uncertainty in compliance costs.
Proposed Fee Structure (Indicative)
Sr. No. | Type of Test / Evaluation | Cost (INR) |
1 | Implantation test | ₹5000 |
2 | Sterility test | ₹2000 |
3 | Surgical dressings | ₹1000 |
4 | Syringes & needles | ₹1000 |
5 | Physical / Physiochemical test | ₹2000 |
6 | Surgical sutures | ₹3000 |
7 | Optical & analytical parameters | ₹250 each |
8 | Quality parameters (absorbency, foreign matter, etc.) | ₹150 each |
9 | Condoms | ₹2500 |
10 | Intrauterine devices | ₹2500 |
11 | Endotoxin testing | ₹3000–₹4500 |
Additional Advantages:
- Transparent pricing helps in accurate financial planning and cost forecasting
- Predictable 5% annual increase ensures long-term visibility
- Flexibility for new or specialized tests through authorized approvals
- Ease of Doing Business
Mandatory integration of testing fees into application processes streamlines approvals and reduces delays—making regulatory pathways more efficient.
Why This Matters for Investors?
- Reduced compliance uncertainty
- Improved product credibility and global acceptance
- Encouragement for domestic manufacturing under “Make in India”
- Enhanced investor confidence through clear and consistent policies
Strategic Outlook
These reforms underline the government’s intent to position India as a preferred destination for medical device manufacturing and investment. With increasing demand in healthcare and a supportive policy environment, the sector is poised for significant growth. Stakeholders are encouraged to participate in the consultation process and help shape a future-ready regulatory framework.
The final rules will be notified after reviewing industry feedback—potentially unlocking the next phase of growth for India’s medical device industry.
Operon Strategist: Enabling Compliance and Growth for Medical Device Manufacturers
Operon Strategist supports medical device manufacturers with expert Regulatory Affairs (RA)
plant setup, and manufacturing guidance. From licensing and dossier preparation to facility setup, QMS, and GMP compliance, they ensure smooth approvals and audit readiness.
With strong industry expertise, Operon helps reduce regulatory risks, optimize costs, and accelerate market entry—making them a trusted partner for growth in India’s evolving medical device sector.